Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4604 in healthy Japanese and Chinese participants
NCT06519968Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of londamocitinib (11 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events at 6 weeks. Started Jul 2024; status: completed.
02
Drugs
londamocitinib
Beyond the preview
Go deeper on NCT06519968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519968.